Allogeneic SCT May Be Effective for Some With Advanced Cutaneous T Cell Lymphomas

Share this content:

the ONA take:

Allogeneic stem cell transplantation may result in long-term remissions in a subset of patients with advanced cutaneous T cell lymphomas (CTCL), a new study published online ahead of print in the journal Annals of Oncology has shown.

Because patients with advanced CTCL and large cell transformation are incurable with standard treatments, researchers from The University of Texas MD Anderson Cancer Center in Houston sought to evaluate the outcomes of patients with advanced CTCL undergoing allogeneic stem cell transplantation.

In the prospective case series, researchers report the outcomes of 47 patients with CTCL who underwent allogeneic stem cell transplantation after failure of standard therapy.

Results showed that 4-year overall survival was 51% and 4-year progression-free survival was 26%. Researchers found that 4-year progression-free survival was superior in patients who had leukemic Sézary Syndrome, a common variant of CTCL, compared with those who did not.

In regard to safety, the cumulative incidences of grades 2 to 4 acute graft-versus-host disease (GVHD) and chronic GVHD were 40% and 28%, respectively.

“Although post-SCT relapse rates are high, many patients respond to immunomodulation and achieve durable remissions,” the authors conclude.

Umbilical cord blood stem cells treat leukemia and lymphoma
Allogeneic stem cell transplantation may result in long-term remissions in a subset of patients with cutaneous T cell lymphomas.
Corresponding Author: Dr. Chitra HosingDepartment of Stem Cell Transplantation and Cell Therapy, Unit 423, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Houston, TX 77030, USA, Phone: +1 713 745 0142; E-mail: cmhosing{at} Background Cutaneous T cell lymphomas (CTCL) and its common variants Mycosis fungoides (MF) and leukemic Sézary Syndrome (SS) are rare extra-nodal non-Hodgkin's lymphomas.
READ FULL ARTICLE From Annals of Oncology
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs